Intelligent Bio Solutions (INBS) AI Stock Analysis

• Market Cap: $10.11M
• Dividend Yield: N/A
• Average Volume (3M): 188.45K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.77
• Revenue Growth: 23.21%
• EPS Growth: 57.43%
• Country: US
• Employees: 50
• Sector: Healthcare
• Sector Strength: 78
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -3.44
• Shares Outstanding: 6,783,543
• 10 Day Avg. Volume: 171,492
• 30 Day Avg. Volume: 188,447
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 3.76
• Price to Cash Flow (P/CF): -1.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Intelligent Bio Solutions' stock score reflects its financial struggles with negative earnings and cash flow but is buoyed by robust corporate strategies and a solid intellectual property portfolio. While technical indicators suggest current weakness, the company's strategic market entry and patent acquisitions provide a foundation for future growth, albeit with significant risks.

Intelligent Bio Solutions Business Overview & Revenue Model

Company Description

Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

How the Company Makes Money

Intelligent Bio Solutions makes money through the sale of its diagnostic tools and therapeutic platforms to healthcare providers, research institutions, and other entities within the biotech industry. The company generates revenue through direct product sales, licensing agreements, and collaborations with strategic partners. These partnerships may include research and development collaborations where INBS receives funding or milestone payments in exchange for access to its proprietary technology. Additionally, the company may engage in service contracts where it provides specialized testing or research services to its clients.

Intelligent Bio Solutions Financial Statement Overview

Summary

Intelligent Bio Solutions is experiencing revenue growth and improvements in gross profit, but it faces challenges due to persistent negative earnings and cash flow. The balance sheet is relatively stable with a manageable debt level, yet the company must focus on improving profitability and cash generation to enhance its financial standing.

Income Statement

INBS has shown a significant improvement in revenue over the past years, with a notable increase in gross profit margin compared to previous periods. However, the company is still struggling with negative EBIT and net income, leading to negative profit margins. The revenue growth is promising, yet profitability remains a key challenge.

Balance Sheet

The company's balance sheet shows a moderate debt-to-equity ratio and a positive equity position, indicating some stability. Stockholders' equity has improved, providing a cushion for liabilities. However, the company needs to address its significant liabilities to improve financial health further.

Cash Flow

INBS has a negative operating cash flow, which raises concerns about its ability to generate cash from operations. The free cash flow is also negative, although there has been a recent influx of financing cash flow. The company needs to improve cash generation to ensure long-term sustainability.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
3.03M	3.11M	1.26M	0.00	1.98M	188.74K
	Gross Profit
1.25M	1.43M	326.67K	0.00	1.98M	188.74K
	EBIT
-10.84M	-10.28M	-12.60M	-8.34M	-5.57M	-2.71M
	EBITDA
-10.10M	-8.81M	-9.47M	30.82K	-1.82M	-561.19K
	Net Income Common Stockholders
-10.69M	-10.16M	-10.63M	-8.31M	-7.04M	-3.16M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
18.07K	6.30M	1.54M	8.24M	12.57M	427.27K
	Total Assets
1.94M	13.78M	10.35M	12.35M	20.40M	2.48M
	Total Debt
5.13M	871.44K	1.34M	0.00	0.00	5.13M
	Net Debt
5.12M	-5.43M	-201.56K	-8.24M	-12.57M	4.71M
	Total Liabilities
7.82M	5.60M	6.67M	5.81M	6.85M	7.69M
	Stockholders Equity
-5.86M	8.33M	3.80M	6.62M	13.61M	-5.19M
Cash Flow		Free Cash Flow
-7.82M	-9.79M	-7.88M	-3.74M	-11.30M	-498.62K
	Operating Cash Flow
-10.12M	-9.57M	-7.38M	-3.36M	-11.30M	-498.62K
	Investing Cash Flow
-176.24K	-221.43K	-694.14K	-880.22K	0.00	-14.00K
	Financing Cash Flow
11.50M	14.56M	1.44M	0.00	23.40M	733.86K

Intelligent Bio Solutions Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INBS, the sentiment is Negative. The current price of 1.5 is below the 20-day moving average (MA) of 1.96, below the 50-day MA of 1.97, and below the 200-day MA of 1.66, indicating a bearish trend. The MACD of -0.14 indicates Positive momentum. The RSI at 32.21 is Neutral, neither overbought nor oversold. The STOCH value of 11.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INBS.

Intelligent Bio Solutions Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CDNA	68 Neutral	$981.04M	18.08	19.46%	―	19.07%	―
NTRA	67 Neutral	$19.01B	―	-19.42%	―	56.75%	59.77%
EXAS	53 Neutral	$8.07B	―	-37.09%	―	10.37%	-389.98%
INBS	52 Neutral	$10.11M	―	-279.80%	―	23.21%	57.43%
ILMN	49 Neutral	$12.42B	―	-30.11%	―	-2.93%	-4.69%
Sector *	48 Neutral	$6.86B	1.11	-50.22%	2.47%	16.71%	1.53%
QDEL	46 Neutral	$2.30B	―	-50.74%	―	-7.03%	-20233.78%

Intelligent Bio Solutions Corporate Events

Intelligent Bio Solutions Secures U.S. Patent for Drug Screening

On March 26, 2025, Intelligent Bio Solutions Inc. announced the granting of a U.S. patent for its Intelligent Fingerprinting Drug Screening Cartridge, marking its sixth active U.S. patent. This patent strengthens the company’s intellectual property portfolio and competitive position as it plans to enter the multi-billion dollar U.S. market in 2025. The patent covers the lateral flow test strip technology used in the company’s drug screening system, which detects drugs in fingerprint sweat. This development is part of INBS’s strategy to leverage the expanding global drug screening market, with a recent FDA 510(k) submission and plans for U.S. market entry.

Intelligent Bio Solutions Anticipates Sixth U.S. Patent Approval

On March 20, 2025, Intelligent Bio Solutions Inc. announced its expectation to receive a sixth U.S. patent, enhancing its intellectual property portfolio for its lateral flow technology used in the Intelligent Fingerprinting Drug Testing Solution. This development is crucial for the company’s strategy to expand its presence in the U.S. drug screening market, as it aims to meet the growing demand for non-invasive testing solutions. The anticipated patent will help protect the company’s proprietary technology as it prepares for U.S. market entry in 2025, positioning it to drive industry transformation and expand its global market presence.

Intelligent Bio Solutions Plans U.S. Market Entry in 2025

On February 10, 2025, Intelligent Bio Solutions Inc. announced its 2024 growth achievements and its strategic plan to enter the U.S. market in 2025. In 2024, the company achieved significant revenue growth of 148% year-over-year, driven by the strong adoption of its drug screening technology. The company completed its FDA 510(k) pre-market notification in December, positioning itself to enter the U.S. drug screening market, which represents a large portion of the global demand. Rising drug positivity rates and increased safety regulations underscore the need for the company’s non-invasive testing solutions. The company anticipates continued growth, focusing on safety-critical industries and leveraging its expanding global customer base.

Intelligent Bio Solutions Partners with Avon Freight Group

On February 7, 2025, Intelligent Bio Solutions announced that Avon Freight Group has adopted its non-invasive Intelligent Fingerprinting Drug Testing Solution for random drug testing at its UK sites. This move by Avon, a significant logistics firm, highlights a shift towards more respectful and efficient drug testing methods, boosting workplace safety and culture. This partnership expands INBS’s network to over 400 accounts in 19 countries, reinforcing its industry leadership as the UK drug testing market is projected to reach $453 million by 2030. The company’s strategic growth, including a planned U.S. expansion following an FDA submission, positions it to address growing demand for scalable and cost-effective drug testing solutions.

Intelligent Bio Solutions Expands Fingerprinting System Globally

On January 31, 2025, Intelligent Bio Solutions announced plans to upgrade its Intelligent Fingerprinting Drug Screening System with multilingual capabilities, enhancing accessibility for over 4 billion users globally. This strategic move supports the company’s international expansion and aligns with its 2025 entry into the US market, tapping into the growing demand for workplace drug testing solutions projected to reach $8 billion by 2030.

Intelligent Bio Solutions Expands with UK Partnership

On January 29, 2025, Intelligent Bio Solutions Inc. announced that Quantum Traffic Management, a UK-based traffic management provider, adopted their Intelligent Fingerprinting Drug Testing Solution across ten sites to enhance workplace testing efficiency and safety. This transition from traditional saliva and urine testing to INBS’s rapid, non-invasive system marks a significant operational improvement for Quantum TM, and underscores INBS’s growing influence in the drug screening market, with over 400 accounts globally and plans to enter the US market in 2025.

Intelligent Bio Solutions Partners with IVY Diagnostics

On January 28, 2025, Intelligent Bio Solutions announced a significant partnership with IVY Diagnostics to expand its Intelligent Fingerprinting Drug Testing Solution in Europe and the Middle East. This collaboration is strategic due to the projected growth of the drug screening market in these regions, with Europe expected to reach $3.6 billion by 2030. IVY Diagnostics, leveraging its extensive network and expertise, will help INBS capture new opportunities, particularly in drug rehabilitation and law enforcement, with ongoing trials in Italy. This partnership positions the company to effectively meet the rising demand for efficient drug screening solutions.